# Arlene Chan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/arlene-chan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 19,067 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 42 |
| i10-index | 107 |
| Last Known Institution | Breast Cancer Research Foundation |
| OpenAlex ID | https://openalex.org/A5005769474 |
| ORCID iD | https://orcid.org/0000-0003-2135-2286 |
| Works | 281 |

## Researcher papers

- [Adjuvant Trastuzumab in HER2-Positive Breast Cancer](https://scholariq.org/papers/adjuvant-trastuzumab-in-her2-positive-breast-cancer/)
- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/neratinib-after-trastuzumab-based-adjuvant-therapy-in-her2-positive-breast/)
- [Challenges to effective cancer control in China, India, and Russia](https://scholariq.org/papers/challenges-to-effective-cancer-control-in-china-india-and-russia/)
- [Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer](https://scholariq.org/papers/randomized-phase-iii-placebo-controlled-trial-of-letrozole-plus-oral/)
- [Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial](https://scholariq.org/papers/abemaciclib-plus-trastuzumab-with-or-without-fulvestrant-versus-trastuzumab-plus/)
- [A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer](https://scholariq.org/papers/a-phase-ii-study-of-abemaciclib-in-patients-with-brain-metastases-secondary-to/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Breast Lesions and Carcinomas](https://scholariq.org/topics/breast-lesions-and-carcinomas/)

## Researcher university

- [Breast Cancer Research Foundation](https://scholariq.org/institutions/breast-cancer-research-foundation/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.